Laboratorios Farmaceuticos RoviLABFF 93 Return-on-Tangible-Equity is 5.95% as of Mar. 2026, which is 73% below its 10-year median of 22.06. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 897 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 81.38% on this metric.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Equity or its related term are showing as below:
LABFF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.57 Med: 22.06 Max: 43.56
Current: 22.45
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Return-on-Tangible-Equity was 43.56%. The lowest was 8.57%. And the median was 22.06%.
LABFF's Return-on-Tangible-Equity is ranked better than 81.38% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs LABFF: 22.45
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Laboratorios Farmaceuticos Rovi Return-on-Tangible-Equity Related Terms
Laboratorios Farmaceuticos Rovi Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LABFF vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.95% mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Return-on-Tangible-Equity of 5.95% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 73% below median its historical median of 22.06. Over the past decade, Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Equity has ranged from 8.57 to 43.56. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #167 out of 897 companies in the Drug Manufacturers industry, placing it in the top 18.6%.
Is Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Equity too high?
Laboratorios Farmaceuticos Rovi's current Return-on-Tangible-Equity of 5.95% is 73% below median its 10-year median of 22.06. Over the past 10 years, this metric has ranged from a low of 8.57 to a high of 43.56. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Laboratorios Farmaceuticos Rovi's value of 5.95% is 24.7% below this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #167 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #167 out of 897 companies for Return-on-Tangible-Equity. This places Laboratorios Farmaceuticos Rovi in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Laboratorios Farmaceuticos Rovi's value of 5.95% is 24.7% below this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Return-on-Tangible-Equity has ranged from 8.57 to 43.56 over the past decade. While the company's 10-year median is 22.06 vs. the industry median of 7.90, Laboratorios Farmaceuticos Rovi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Return-on-Tangible-Equity of 5.95% is 24.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Return-on-Tangible-Equity is 5.95%, which is 73% below median its own 10-year median of 22.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Return-on-Tangible-Equity of 5.95%. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Return-on-Tangible-Equity is 5.95%, which is 73% below median its 10-year median of 22.06 and 24.7% below the Drug Manufacturers industry median of 7.90. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Return-on-Tangible-Equity is 5.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
Return-on-Tangible-Equity: 5.95% (73% below median its 10-year median of 22.06)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 24.7% below the Drug Manufacturers median (#167 of 897)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
